JPMorgan Chase & Co. Reaffirms “Neutral” Rating for GlaxoSmithKline plc (NYSE:GSK)

JPMorgan Chase & Co. reissued their neutral rating on shares of GlaxoSmithKline plc (NYSE:GSK) in a research note issued to investors on Wednesday, October 18th.

Other analysts have also issued research reports about the stock. Argus restated a buy rating and issued a $50.00 price target on shares of GlaxoSmithKline plc in a research note on Thursday, August 31st. Zacks Investment Research upgraded shares of GlaxoSmithKline plc from a hold rating to a buy rating and set a $47.00 price target for the company in a research note on Tuesday, July 18th. TheStreet lowered shares of GlaxoSmithKline plc from a b rating to a c+ rating in a research note on Wednesday, July 26th. Citigroup Inc. lowered shares of GlaxoSmithKline plc from a buy rating to a neutral rating in a research note on Wednesday, July 5th. Finally, BidaskClub upgraded shares of GlaxoSmithKline plc from a strong sell rating to a sell rating in a research note on Friday, August 25th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $44.33.



Shares of GlaxoSmithKline plc (NYSE GSK) opened at 36.60 on Wednesday. The stock has a market capitalization of $89.45 billion, a PE ratio of 35.47 and a beta of 1.03. GlaxoSmithKline plc has a 12 month low of $36.51 and a 12 month high of $44.54. The stock’s 50 day moving average is $40.48 and its 200 day moving average is $41.49.

GlaxoSmithKline plc (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline plc had a net margin of 17.79% and a return on equity of 461.88%. Analysts anticipate that GlaxoSmithKline plc will post $2.89 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Reaffirms “Neutral” Rating for GlaxoSmithKline plc (NYSE:GSK)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/27/glaxosmithkline-plc-gsk-earns-neutral-rating-from-j-p-morgan-chase-co-3.html.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a $0.5037 dividend. The ex-dividend date is Thursday, November 9th. This represents a $2.01 annualized dividend and a yield of 5.51%. This is an increase from GlaxoSmithKline plc’s previous quarterly dividend of $0.49. GlaxoSmithKline plc’s dividend payout ratio is presently 162.30%.

Hedge funds have recently bought and sold shares of the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in GlaxoSmithKline plc by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after acquiring an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC raised its position in GlaxoSmithKline plc by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after acquiring an additional 1,990 shares in the last quarter. Westwood Holdings Group Inc. raised its position in GlaxoSmithKline plc by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after acquiring an additional 400 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its position in GlaxoSmithKline plc by 1.9% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after acquiring an additional 64 shares in the last quarter. Finally, FTB Advisors Inc. raised its position in GlaxoSmithKline plc by 16.9% in the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after acquiring an additional 539 shares in the last quarter. 9.31% of the stock is owned by institutional investors and hedge funds.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply